<DOC>
	<DOC>NCT02315144</DOC>
	<brief_summary>The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV48108.</brief_summary>
	<brief_title>An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Stage 1 (Healthy Volunteers) Male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg with a body mass index (BMI) of less than 30 kg/m^2. In good health as determined by medical and psychiatric history, physical examination, electrocardiogram (ECG), serum chemistry, hematology, urinalysis, and serology. Other criteria apply, please contact the investigator for more information Stage 2 (Chronic Obstructive Lung Disease (COPD) patients) Male or female; 40 to 75 years of age, inclusive with a minimum body weight of 40 kg Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack years at the screening visit Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines. Other criteria apply, please contact the investigator for more information Stage 1 (Healthy Volunteers) History or current evidence of a clinically significant or uncontrolled disease Any disorder that may interfere with the absorption, distribution, metabolism or excretion of study drugs. History of severe allergy to milk protein Active smokers or former smokers who quit within 3 months of the first dose of study drug. Former smokers with greater than fivepack years (ie, the equivalent of one pack per day for five years) are also excluded. Other criteria apply, please contact the investigator for more information Stage 2 (Chronic Obstructive Lung Disease (COPD) patients) Recent history of hospitalization due to an exacerbation of airway disease within 3 months Need for increased treatments of COPD within 6 weeks prior to the screening visit History of and/or current diagnosis of asthma Known α1 antitrypsin deficiency, active lung infections (such as tuberculosis or pneumonia), and lung cancer are absolute exclusionary conditions Other criteria apply, please contact the investigator for more information</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>COPD</keyword>
	<keyword>bronchodilation</keyword>
</DOC>